An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

BACKGROUND: Apatinib has been proved to be effective and well tolerated among patients in phase II and III studies. Here, we evaluated the safety and effectiveness of apatinib in advanced gastric cancer patients in a real-world setting. METHODS: This study enrolled advanced gastric cancer patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiang, Zhang, Ruixing, Du, Nan, Yang, Mudan, Zang, Aimin, Liu, Likun, Yu, Junyan, Gao, Jinghua, Zhang, Junping, Fu, Zhanzhao, Ren, Yuchuan, Ma, Liwen, Guo, Jun, Li, Qingshan, Li, Xiaomei, Fan, Zaiwen, Song, Xiang, Liu, Zheng, Zhang, Yan, Li, Guozhong, Yu, Zhonghe, Diao, Jianfeng, Jia, Junmei, Liang, Feng, Wang, Huaqing, Sun, Junzhong, Gao, Yunge, Yang, Ping, Bai, Chunmei, Ren, Xiubao, Zhong, Diansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082876/
https://www.ncbi.nlm.nih.gov/pubmed/32218807
http://dx.doi.org/10.1177/1758835920905424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082876/
https://www.ncbi.nlm.nih.gov/pubmed/32218807
http://dx.doi.org/10.1177/1758835920905424

Ejemplares similares